Anebulo Pharmaceuticals I... (ANEB)

AI Score

Unlock

1.01

-0.03 (-2.88%)

At close: Apr 17, 2025, 3:59 PM

1.01

0.00%

After-hours: Apr 17, 2025, 04:05 PM EDT

Anebulo Pharmaceuticals Income Statement

Financials in USD. Fiscal year is July - June.

Fiscal Year	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-2.59M	-2.41M	-1.34M	-1.66M	-2.76M	-2.54M	-2.49M	-2.86M	-3.81M	-2.61M	-2.33M	-1.88M	-1.07M	-1.55M	-2.48M	-552.13K	-324.57K	-252.35K	-173.35K
Interest Income	7.07K	26.01K	50.22K	68.08K	75.52K	55.2K	6.00	79.15K	8.82K	n/a	1.93K	n/a	n/a	n/a	1.02K	n/a	n/a	n/a	n/a
Pretax Income	-2.46M	-2.2M	-1.35M	-1.65M	-2.72M	-2.48M	-2.5M	-2.8M	-3.83M	-2.61M	-2.32M	-1.88M	-1.07M	-1.55M	-29.11M	-555.83K	-328.6K	-256.38K	-174.64K
Net Income	-2.46M	-2.2M	-1.35M	-1.65M	-2.72M	-2.48M	-2.5M	-2.8M	-3.84M	-2.61M	-2.32M	-1.87M	-1.07M	-1.55M	-29.11M	-555.83K	-328.6K	-256.38K	-174.64K
Selling & General & Admin	1.37M	1.1M	872.66K	915.91K	1.7M	1.27M	1.08M	1.77M	1.94M	1.39M	1.21M	964.28K	858.19K	839.83K	678.01K	279.09K	154.59K	232.06K	23.35K
Research & Development	1.22M	1.31M	467.71K	748.34K	1.06M	1.27M	1.42M	1.09M	1.87M	1.22M	1.12M	915.36K	212.94K	715.1K	1.81M	273.04K	169.98K	20.29K	150K
Other Expenses	n/a	n/a	n/a	2.32K	-594	7.66K	-1.2K	n/a	-13.83K	212.00	813.00	3.15K	-1.87K	1.53K	-1.34K	-3.7K	-4.03K	-4.03K	n/a
Operating Expenses	2.59M	2.41M	1.34M	1.66M	2.76M	2.54M	2.49M	2.86M	3.81M	2.61M	2.33M	1.88M	1.07M	1.55M	2.48M	552.13K	324.57K	252.35K	173.35K
Interest Expense	59.7K	59.7K	59.7K	59.7K	31.84K	n/a	52.45K	n/a	13.83K	n/a	1.93K	n/a	1.87K	n/a	8.07K	3.7K	n/a	n/a	1.29K
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	2.59M	2.41M	1.34M	1.66M	2.76M	2.54M	2.49M	2.86M	3.81M	2.61M	2.33M	1.88M	1.07M	1.55M	2.48M	552.13K	324.57K	252.35K	-173.35K
Income Tax Expense	n/a	n/a	n/a	-1.66M	-2.76K	-57.74K	52.45K	n/a	13.83K	-2.61M	-4.67K	-3.15K	1.87K	-1.55M	-1.02K	-1.1M	-324.57K	-252.35K	n/a
Shares Outstanding (Basic)	27.42M	25.93M	25.82M	25.93M	25.79M	25.63M	25.63M	25.63M	25.63M	23.42M	23.34M	23.34M	23.34M	23.34M	18.29M	23.27M	23.27M	23.27M	23.72M
Shares Outstanding (Diluted)	27.42M	25.93M	25.82M	25.93M	25.79M	25.63M	25.63M	25.63M	25.63M	23.42M	23.34M	23.34M	23.34M	23.34M	18.29M	23.27M	23.27M	23.27M	23.72M
EPS (Basic)	-0.09	-0.08	-0.05	-0.06	-0.11	-0.1	-0.1	-0.11	-0.15	-0.11	-0.1	-0.08	-0.05	-0.07	-1.59	-0.02	-0.01	-0.01	-0.01
EPS (Diluted)	-0.09	-0.08	-0.05	-0.06	-0.11	-0.1	-0.1	-0.11	-0.15	-0.11	-0.1	-0.08	-0.05	-0.07	-1.59	-0.02	-0.01	-0.01	-0.01
EBITDA	-2.4M	-2.14M	-1.29M	-1.59M	-2.76M	-2.54M	-2.49M	-2.8M	-3.81M	n/a	2.74K	-1.88M	-1.07M	-1.55M	-29.11M	-552.13K	-4.03K	-4.03K	-173.35K
EBIT	-2.4M	-2.14M	-1.29M	-1.59M	-2.69M	-2.54M	-2.49M	-2.8M	-3.83M	-2.61M	-2.32M	-1.88M	-1.07M	-1.55M	-29.11M	-552.13K	-324.57K	-252.35K	-173.35K
Depreciation & Amortization	n/a	271.09K	50.1K	1.66M	2.76K	2.54M	2.49M	66.07K	3.81M	2.61M	2.33M	1.88M	1.07M	1.55M	2.48M	552.13K	324.57K	252.35K	n/a